RxDoctor Payments Data

Lindsay Yateman

Family · Lapeer, MINPI 1154913747

Payments from drug & device makers

$7,267in general payments, 2019–2025

Across 259 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Coloplast$641
  • Dendreon Pharmaceuticals LLC$514
  • Merck$459
  • Sumitomo Pharma America, Inc.$404
  • Pfizer$335
  • plus $3K from 31 others

What the payments were for

  • Travel & lodging$1,72324%
  • Food & beverage$5,45975%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,267 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron77$63,141
MyrbetriqMirabegron53$36,381
Mirabegron ErMirabegron35$25,085
Tamsulosin Hcl311$5,217
Oxybutynin Chloride ErOxybutynin Chloride124$3,644
Tolterodine Tartrate ErTolterodine Tartrate38$3,216
Estradiol42$2,891
Methenamine Hippurate40$2,814
Trospium Chloride25$2,406
Finasteride121$2,233
Cephalexin153$2,105
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst129$1,653
Trimethoprim24$1,258
Alfuzosin Hcl ErAlfuzosin Hcl51$1,157
NitrofurantoinNitrofurantoin Macrocrystal27$863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$404$63,14177 claims
Astellas Pharma US IncMyrbetriq$150$36,38153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Lapeer

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →